NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Vaxcyte, Inc. (PCVX) Stock Analysis

Vaxcyte, Inc. (PCVX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PCVX

$61.16

−$0.01 (−0.02%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PCVX with… →

PCVX Key Statistics

As of Sep 4, 2026
Trading
Open
$59.73
Previous Close
$61.17
Day's Range
59.65–61.78
52-Week Range
30.81–65.00
Volume
986.70K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.22
Valuation
Market Cap
$9.10B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−7.62
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$766.63M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
148.81M
1-Year Return
+90.23%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
1.30M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PCVX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+32.55%
2025−43.64%
2024+30.35%
2023+30.97%
2022+101.56%
2021−10.46%
2020 (partial year)+1.61%

As of September 4, 2026.

PCVX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$766.63M—
2024$0.00−$463.93M—
2023$0.00−$402.27M—
2022$0.00−$223.49M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$923.68M−$766.63M—
2024$0.00—−$569.55M−$463.93M—
2023$0.00—−$393.04M−$402.27M—
2022$0.00—−$209.26M−$223.49M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PCVX Valuation vs Biotechnology Median

Median of 656 stocks
MetricPCVXBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vaxcyte, Inc. (PCVX) at $9.10B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 507.

The 52-week range on file runs from $30.81 to $65.00. PCVX last closed at $61.16 on September 4, 2026. That is −$0.01 (−0.02%) against the previous close. The latest close sits 98.51% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $766.63M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −7.62.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +90.23%. Across 5 years the annualized return works out at +18.97%. The reported beta is 1.22. Annualized volatility over the trailing 6 years is 64.23%.

Growth & Income

No dividend is on file for PCVX.

So far in 2026 the price is +32.55%. Across the complete calendar years on file, 2022 returned +101.56% and 2025 returned −43.64%. Of the 5 complete calendar years on file, 3 finished higher.

Peer Comparison

Vaxcyte, Inc. (PCVX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Vaxcyte, Inc. PCVX $9.10B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Vaxcyte, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Visit website →